001     285044
005     20260209103229.0
024 7 _ |a 10.1002/mds.70084
|2 doi
024 7 _ |a pmid:41070559
|2 pmid
024 7 _ |a pmc:PMC12882042
|2 pmc
024 7 _ |a 0885-3185
|2 ISSN
024 7 _ |a 1531-8257
|2 ISSN
037 _ _ |a DZNE-2026-00168
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Lischewski, Stella Andrea
|0 0000-0003-1165-9153
|b 0
245 _ _ |a Analysis of a Modified Version of the Inventory of Non-Ataxia Signs Over 12 Years in Patients with Friedreich's Ataxia in the EFACTS Study.
260 _ _ |a New York, NY
|c 2026
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1770629143_24270
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Friedreich's ataxia is a rare, neurodegenerative, multisystem disorder. While ataxia is a hallmark, non-ataxia signs, including muscle weakness, spasticity, and dysphagia are equally disabling. The Inventory of Non-Ataxia Signs (INAS) is a symptom list transformable to a 16-item count.To evaluate the responsiveness of a modified INAS in this population.Participants were drawn from the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS). The modified INAS count (presence/absence, 0-16 scale) and modified INAS sum (severity-weighted, 0-84 scale) were evaluated using linear mixed-models and standardized response means (SRMs). Items rare (<5%) and uncharacteristic in Friedreich's ataxia were excluded (chorea, myoclonus, fasciculations, resting tremor, rigidity) RESULTS: A total of 1129 participants (mean age, 32.3 years) were assessed for up to 12 years. The mean modified INAS count was 4.6 (±2.2) and modified INAS sum 15.1 (± 9.9). Both correlated strongly with existing outcome measures. Longitudinally, the modified INAS count increased by 0.13 points/year (95% CI 0.12, 0.14; P < 0.001) and modified INAS sum by 0.68 points/year (95% CI 0.64, 0.72; P < 0.001). The modified INAS sum demonstrated greater responsiveness, with SRMs of 0.26, 0.38, 0.53, and 0.80 at 1, 2, 3, and 5 years, respectively, compared with 0.16, 0.27, 0.31, and 0.46 for the modified INAS count. In non-ambulatory patients and children, responsiveness of the modified INAS sum was higher (SRM 0.82 and 1.7 at 5 years, respectively).The modified INAS sum showed good responsiveness over 5 years but not over 1-3 years. It may supplement existing outcome measures, contributing to holistic assessment of this multisystem disease, especially in non-ambulatory patients, in whom ataxia-focused measures may show ceiling effects, and children, who typically progress faster. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Friedreich's ataxia
|2 Other
650 _ 7 |a longitudinal
|2 Other
650 _ 7 |a non‐ataxia symptoms
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Friedreich Ataxia: diagnosis
|2 MeSH
650 _ 2 |a Friedreich Ataxia: physiopathology
|2 MeSH
650 _ 2 |a Friedreich Ataxia: complications
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Young Adult
|2 MeSH
650 _ 2 |a Severity of Illness Index
|2 MeSH
650 _ 2 |a Adolescent
|2 MeSH
650 _ 2 |a Child
|2 MeSH
700 1 _ |a Dogan, Imis
|b 1
700 1 _ |a Giunti, Paola
|0 0000-0003-3508-4788
|b 2
700 1 _ |a Parkinson, Michael H
|b 3
700 1 _ |a Mariotti, Caterina
|0 0000-0003-2405-3564
|b 4
700 1 _ |a Durr, Alexandra
|b 5
700 1 _ |a Ewenczyk, Claire
|0 0000-0002-4864-6287
|b 6
700 1 _ |a Boesch, Sylvia
|b 7
700 1 _ |a Nachbauer, Wolfgang
|b 8
700 1 _ |a Klopstock, Thomas
|0 P:(DE-2719)2810704
|b 9
|u dzne
700 1 _ |a Stendel, Claudia
|0 P:(DE-2719)2812141
|b 10
700 1 _ |a de Rivera Garrido, Francisco Javier Rodríguez
|b 11
700 1 _ |a Schöls, Ludger
|0 P:(DE-2719)2810795
|b 12
|u dzne
700 1 _ |a Fleszar, Zofia
|0 P:(DE-2719)9000074
|b 13
|u dzne
700 1 _ |a Klockgether, Thomas
|0 P:(DE-2719)2810314
|b 14
700 1 _ |a Grobe-Einsler, Marcus
|0 P:(DE-2719)9001510
|b 15
700 1 _ |a Giordano, Ilaria
|0 P:(DE-2719)2811662
|b 16
|u dzne
700 1 _ |a Rai, Myriam
|b 17
700 1 _ |a Pandolfo, Massimo
|b 18
700 1 _ |a Jacobi, Heike
|0 P:(DE-2719)2811564
|b 19
700 1 _ |a Hilgers, Ralf-Dieter
|b 20
700 1 _ |a Schulz, Jörg B
|b 21
700 1 _ |a Reetz, Kathrin
|0 0000-0002-9730-9228
|b 22
700 1 _ |a Group, EFACTS Study
|b 23
|e Collaboration Author
700 1 _ |a Indelicato, Elisabetta
|b 24
|e Contributor
700 1 _ |a Amprosi, Matthias
|b 25
|e Contributor
700 1 _ |a Gellera, Cinzia
|b 26
|e Contributor
700 1 _ |a Mongelli, Alessia
|b 27
|e Contributor
700 1 _ |a Castaldo, Anna
|b 28
|e Contributor
700 1 _ |a Fichera, Mario
|b 29
|e Contributor
700 1 _ |a Bertini, Enrico
|b 30
|e Contributor
700 1 _ |a Vasco, Gessica
|b 31
|e Contributor
700 1 _ |a Biet, Marie
|b 32
|e Contributor
700 1 _ |a Monin, Marie Lorraine
|b 33
|e Contributor
700 1 _ |a Holtbernd, Florian
|b 34
|e Contributor
700 1 _ |a Brcina, Nikolina
|b 35
|e Contributor
700 1 _ |a Hohenfeld, Christian
|b 36
|e Contributor
700 1 _ |a Radelfahr, Florentine
|b 37
|e Contributor
700 1 _ |a Bischoff, Almut
|0 P:(DE-2719)9003293
|b 38
|e Contributor
|u dzne
700 1 _ |a Hayer, Stefanie
|0 P:(DE-2719)2813263
|b 39
|e Contributor
|u dzne
700 1 _ |a Koutsis, Georgios
|b 40
|e Contributor
700 1 _ |a Breza, Marianthi
|b 41
|e Contributor
700 1 _ |a Palau, Francesc
|b 42
|e Contributor
700 1 _ |a O'Callaghan, Mar
|b 43
|e Contributor
700 1 _ |a Thomas-Black, Gilbert
|b 44
|e Contributor
700 1 _ |a Manso, Katarina
|b 45
|e Contributor
700 1 _ |a Solanky, Nita
|b 46
|e Contributor
700 1 _ |a Labrum, Robyn
|b 47
|e Contributor
773 _ _ |a 10.1002/mds.70084
|g Vol. 41, no. 1, p. 200 - 211
|0 PERI:(DE-600)2041249-6
|n 1
|p 200 - 211
|t Movement disorders
|v 41
|y 2026
|x 0885-3185
856 4 _ |u https://pub.dzne.de/record/285044/files/DZNE-2026-00168.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/285044/files/DZNE-2026-00168.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2810704
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2812141
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2810795
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 13
|6 P:(DE-2719)9000074
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2810314
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)9001510
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 16
|6 P:(DE-2719)2811662
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 38
|6 P:(DE-2719)9003293
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 39
|6 P:(DE-2719)2813263
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-11-10
|w ger
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-11-10
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOVEMENT DISORD : 2022
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-11-10
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-10
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-11-10
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOVEMENT DISORD : 2022
|d 2025-11-10
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
920 1 _ |0 I:(DE-2719)1011001
|k Clinical Research (Bonn)
|l Clinical Research Coordination
|x 1
920 1 _ |0 I:(DE-2719)5000005
|k AG Schöls
|l Clinical Neurogenetics
|x 2
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies (Bonn)
|l Patient Studies (Bonn)
|x 3
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a I:(DE-2719)5000005
980 _ _ |a I:(DE-2719)1011101
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21